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11β-HSD2 11β-hydroxysteroid dehydrogenase type 2 
ACE angiotensin converting enzyme  
ACEI angiotensin converting enzyme inhibitor 
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ARB angiotensin II type-1 receptor blocker 
AngI angiotensin I 
AngII angiotensin II 
AT1R angiotensin II type-1 receptor 
AT2R angiotensin II type-2 receptor 
CHF congestive heart failure 
CKD chronic kidney disease 
DCM dilated cardiomyopathy  
DRI direct renin inhibitor 
GFR glomerular filtration rate 
HCM hypertrophic cardiomyopathy  
HFpEF heart failure with preserved ejection fraction 
HFrEF heart failure with reduced ejection fraction  
HTN systemic hypertension 
MMVD myxomatous mitral valve disease  
MR mineralocorticoid receptor  
MRA mineralocorticoid receptor antagonist 
RAAS renin angiotensin aldosterone system 
UAldo:C urine aldosterone to creatinine ratio  
UP:C urine protein to creatinine ratio 
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Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and 
perpetuates the syndromes of congestive heart failure (CHF), systemic hypertension (HTN), and 
chronic kidney disease (CKD).  Excessive circulating and tissue angiotensin II (AngII) and 
aldosterone levels lead to a pro-fibrotic, - inflammatory, and -hypertrophic milieu that causes 
remodeling and dysfunction in cardiovascular and renal tissues.  Our understanding the RAAS’s 
role in this pathologic remodeling has grown over the past few decades and numerous medical 
therapies aimed at suppressing the RAAS have been developed.  Despite this, morbidity from 
these diseases remains high.  Continued investigation into the complexities of the RAAS should 
help us modulate (suppress or enhance) components of this system and improve quality of life 
and survival.  This review focuses on updates in our understanding of the RAAS and the 
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pathophysiology of AngII and aldosterone excess, reviewing what is known about its 
suppression in cardiovascular and renal diseases, especially in the cat and dog.   
 
Introduction  
Although RAAS activation can be compensatory in the early stages of cardiovascular and renal 
disease, long-term activation is maladaptive.  The relative increase in plasma renin activity and 
blood aldosterone and norepinephrine concentrations in human patients are therefore considered 
markers of, and contributors to, the hemodynamic and anatomic derangements of this 
syndrome.1-5  The adverse effects of chronic exposure to high concentrations of AngII and 
aldosterone are outlined in Table 1.6-14 Suppression of RAAS is a key strategy in the therapy of 
chronic cardiovascular and renal disease and is achieved by the administration of angiotensin 
converting enzyme inhibitors (ACEI), AngII type-1 receptor blockers (ARB), and 
mineralocorticoid receptor antagonists (MRA), alone or in combination.  The more we learn 
about this system, however, the broader and more complex it becomes. Redundancies that bypass 
our therapeutic blockade or inadvertent suppression of beneficial components of this system 
might reduce the efficacy of our RAAS suppressive therapies.  Angiotensin II and aldosterone 
levels occasionally rise despite pharmacologic RAAS suppression, and the underlying 
mechanisms are still not well understood.15-32  The RAAS is also continuously adapting to the 
individual’s metabolic state, underlying disease process, and therapy.  Some drugs and treatment 
strategies used to treat cardiovascular disease, including furosemide, amlodipine, hydralazine 
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and dietary sodium restriction, also stimulate the RAAS (Supplemental Figure 1).5,33-39 
Continued research into this complex system is necessary to improve medical therapies for 
cardiovascular and renal diseases, allowing us to more adeptly modulate this system and improve 
clinical outcomes.   
 
Circulating and tissue renin angiotensin aldosterone systems 
Renin is synthesized as preprorenin in the juxtaglomerular epithelioid cells, cleaved to prorenin, 
and either released as prorenin or further processed to form active renin, which is stored in 
granules. Renin granules are then released in a controlled manner, making renin the rate-limiting 
step of the renin-angiotensin-aldosterone cascade in most species.  Conversely, angiotensinogen 
is constitutively released from the liver (Figure 1), and is usually present in excess when 
compared to renin. Increased renin synthesis and release occur in situations of low systemic 
blood pressure, hypovolemia, sodium deprivation, and sympathetic stimulation.  Short-term 
activation is beneficial, resulting in improved cardiac output and blood pressure. In the 
circulation, renin metabolizes angiotensinogen, liberating angiotensin I (AngI).  Angiotensin 
converting enzyme (ACE), which is released from endothelial cells, converts AngI to AngII.  
AngII acts at 2 receptors, the angiotensin type-1 and type-2 receptors (AT1R and AT2R).  
AngII’s actions at the AT1R leads to increased sodium retention, vasoconstriction (including 
preferential constriction of the efferent arteriole of the kidney), stimulation of thirst and desire 
for salt, enhanced sympathetic nervous system activity, and aldosterone release from the adrenal 
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gland’s zona glomerulosa.  The interaction of AngII at this receptor mediates much of the 
pathologic changes associated with chronic RAAS activation summarized in Table 1.  Actions of 
AT2R-stimulation are counter-regulatory to those of the AT1R, where stimulation leads to anti-
inflammatory, anti-fibrotic, and vasodilatory effects.  The AT2R is the dominant receptor type in 
the fetus and plays a key role in development, but is less relevant in the normal adult. The AT2R, 
however, might be up-regulated in certain disease states.40-42  
 
Aldosterone, the terminal hormone of RAAS, exerts 90% of the mineralocorticoid activity of 
adrenal secretions, and is a key regulator of sodium, potassium, and body fluid balance.43,44 
Angiotensin II and increased extracellular K+ concentration, the strongest secretagogues for 
aldosterone, increase expression of the CYP11B2 gene, which encodes aldosterone synthase.45 
Acting via the mineralocorticoid receptor (MR), aldosterone modulates the expression of ion 
channels, pumps, and exchangers in epithelial tissues (kidney, colon, and salivary and sweat 
glands).  This ultimately leads to an increase in transepithelial Na+ and water reabsorption and 
K+ excretion.  Mineralocorticoid receptors are also found in non-epithelial tissues such as the 
retina, brain, myocardium, vascular smooth muscle cells, macrophages, fibroblasts, and 
adpiocytes.46-50 Aldosterone’s effects are therefore wide spread, extending well beyond its role as 
a ‘renal hormone’.  Specifically, aldosterone is thought to mediate inflammation and affect 
energy metabolism in non-epithelial tissues.50   
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The unbound MR is primarily located in the cytoplasm and when bound by ligand it is shuttled 
to the nucleus where it acts as a transcription factor.51 Some actions of aldosterone are non-
genomic and occur relatively rapidly. These actions are likely mediated by several mechanisms: 
activation of the small fraction of cell membrane localized MR and MR interaction with other 
receptors such as the G-protein coupled estrogen receptor, AT1R, and epidermal growth factor 
receptor.52 Aldosterone is the primary physiological ligand of the MR, though glucocorticoids, 
such as cortisol have a similar receptor affinity.  In epithelial cells and vascular smooth muscle 
cells, the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) alters the 
glucocorticoids and prevents their binding to the MR. Thus, more abundant glucocorticoids are 
prevented from out-competing mineralocorticoids for the MR. In tissues such as the myocardium 
where 11β-HSD2 is scarce, cortisol binding to the MR is likely important.53   
 
Angiotensin peptides and aldosterone are also produced in tissues such as brain, blood vessels, 
kidneys, and the heart.40,54-57  Locally produced RAAS hormones play important roles in normal 
cardiovascular function and electrolyte-fluid homeostasis, yet also mediate pathologic 
remodeling in the tissues.  In vitro work on cultured vascular smooth muscle cells and 
cardiomyocytes has shown that aldosterone up-regulates components of the RAAS, including 
ACE activity and AngII-stimulated signal transduction, leading to increased local (tissue) 
activity of the RAAS.58-62 These local or tissue RAAS components are also modulated by 
mechanical stretch of the myocardium and vessels, adipocyte secretions, presence of reactive 
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oxygen species (ROS), and inflammation.63,64 Although the amount of aldosterone produced in 
the tissues is normally < 1% of the amount produced by the adrenal glands56,65, locally produced 
aldosterone likely plays a role in pathologic remodeling (hypertrophy and fibrosis), and tissue 
RAAS management will likely be part of future pharmacotherapeutic strategy.11,12,40  
 
Recently, attention has turned toward the prorenin receptor ((P)RR), which binds both renin and 
prorenin, and is a multifunctional receptor found in several locations within the kidney, as well 
as the heart, adipose tissue, and brain.66 The diverse roles of this receptor include maintenance of 
intra- and extracellular pH, central regulation of blood pressure, and sodium homeostasis in the 
kidney.  The role this receptor plays in the pathophysiology of cardiovascular and renal diseases 
remains unanswered, yet it is known that the (P)RR binds prorenin and renders it active in the 
tissues, enabling the local generation of angiotensin peptides.54,66,67  
 
The quest to find novel/alternative pathways of angiotensin generation and metabolism led to the 
discovery of angiotensin (1,12) and (1,25), which are found in cardiovascular and renal tissues 
and serve as precursors for angiotensin peptides such as AngII (Figure 2).68,69 Chymase catalyzes 
the formation of AngII from both angiotensin (1,12) and AngI, allowing ACE-independent 
formation of AngII in the tissue, and this pathway is likely the primary generator of tissue 
AngII.69-71 In fact, chymase has been labeled the ‘most efficient AngII-forming enzyme’ and is 
released from mast cells, cardiac fibroblasts, and vascular endothelial cells during acute and 
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chronic tissue injury and remodeling.72-74 Chymase activation results in pro-fibrotic, anti-fibrotic, 
or pro-inflammatory phenotypes, with the exact phenotype or combination of phenotypes 
depending upon the tissue type and the nature and timing of the stress.75 Chymase is an 
important player in AngII formation (and a pro-fibrotic phenotype) in cardiac disease.76,77 
Chymase is also hypothesized to exacerbate cell death and mitochondrial injury after cardiac 
ischemia/reperfusion.78 Additionally, mast cell activation, and increased release of mediators 
such as chymase has been implicated in the pathophysiology of cardiometabolic disease, such as 
diabetes mellitus and obesity.79   The phenotype of chymase activation differs in canine models 
of hemodynamic overload and might contribute to both extracellular matrix degradation and 
fibrosis formation, contributing to, or counter-balancing ventricular dilation.80-84  
 
The metabolism/degradation of angiotensin peptides is of interest as these pathways can reduce 
levels of AngI and AngII and result in peptides that are ‘active’ and, in some cases, counter-
regulatory to RAAS activation.  A counter-regulatory pathway, the ACE2-Angiotensin(1,7)-Mas 
axis, is currently being investigated, as it appears to elicit protective actions, including 
vasodilation and increased nitric oxide synthesis.40,54 The generation of Angiotensin(1,7) 
[Ang(1,7)] in the heart and brain arises from both ACE2 processing of AngII, whereas in the 
circulation and kidney, Ang(1,7) arises from processing of angiotensin I by endopeptidases, such 
as neprilysin.54,85 Angiotensin(1,7) and its metabolite Ala1-Ang(1,7) bind the Mas and Mas-
related G protein-coupled receptor and elicit the effects noted above.86  The expression of Mas 
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receptors has been most thoroughly explored in rats and mice, where it is expressed in brain, 
testis, kidney, heart, and vessels, with expression patterns changing with age.87 Current research 
is exploring the role of this counter-regulatory pathway in the pathophysiology of cardiovascular 
and renal disease. 
 
The actions of other newly discovered angiotensin peptides are also being studied and might 
reveal pharmacologic targets for both up- and down-regulation.  For example, angiotensin I can 
also be metabolized by ACE2 to form to Ang(1,9), which appears to bind at the AT2R.88 Also, 
AngII is metabolized by aminopeptidase A to form angiotensin III, which like its parent peptide, 
is capable of binding both the AT1R and AT2R.89 Angiotensin III can then be metabolized to 
angiotensin IV via aminopeptidase N.  Both of these angiotensin peptides lead to increased atrial 
stretch-induced atrial natriuretic peptide secretion in animal models, via the AT2R and the 
insulin-regulated aminopeptidase, respectively.90,91 For a more comprehensive review of tissue 
RAAS, novel RAAS components, and the production of aldosterone in tissues, the reader is 
referred elsewhere.40,42,54,55   
 
Chronobiology of the RAAS 
RAAS peptides and antidiuretic hormones oscillate in a circadian (approximately 24 hours) 
periodicity.92-94 This leads to day-night variation in urine flow rate, urinary electrolyte excretion, 
and blood pressure.  The circadian ‘clock’ begins at the cellular level where transcriptional and 
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translational regulators induce expression of multiple genes that ultimately dictate the metabolic 
rates and homeostasis of an organism.95  Central clocks, residing in the brain, and local cellular 
clocks respond to environmental and metabolic signals, allowing the organism to adapt to 
changing circumstances.  The time-variant fluctuations in RAAS hormones in dogs92,96 is, similar 
to humans and urine flow and sodium excretion have diurnal peaks whereas urine osmolality and 
potassium excretion have nocturnal peaks.  A more recent and detailed characterization of the 
chronobiology of these peptides show that, in dogs fed a once daily (A.M.) normal sodium meal, 
that renin activity and the urinary aldosterone to creatinine ratio (UAldo:C) decrease after 
feeding, then rise throughout the afternoon, peaking in the evening.97  Systemic blood pressure 
oscillates in parallel with RAAS peptides, increasing in the first half of the night, decreasing as 
morning approaches, which is opposite to what is described in healthy adult humans.98  The 
timing of feeding also affects the circadian rhythm of both the RAAS and systemic blood 
pressure suggesting that dietary sodium is a key mediator of this modulation.97,99  An improved 
understanding of RAAS chronobiology has implications in both the characterization and 
quantification of RAAS activity and will likely inform the timing of drug administration.100,101   
 
RAAS, Renal Hemodynamics and Tubular Function 
The principal effects of AngII in the kidney include vasoconstriction of the interlobular artery 
and afferent and efferent arterioles (greatest effect on the latter), enhanced afferent arteriolar 
response to tubuloglomerular feedback, and constriction of the glomerular mesangium.  The net 
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result of these changes is an increase in filtration fraction.  RAAS activation enhances sodium 
reabsorption throughout the renal tubules with AngII effects greatest at the proximal tubule and 
loop of Henle and aldosterone effects greatest at the distal convoluted tubule and collecting duct.  
Changes in renal perfusion pressure can also elicit biophysical and paracrine effects, such as 
increased generation of ATP, nitric oxide, and ROS, and induction of cyclooxygenase enzymes 
that lead to a pressure natriuresis.102-104  This allows the kidney to ‘escape’ from the sodium 
retaining effects of excess AngII (and increased aldosterone production).105  Natriuretic peptides 
also counterbalance increases in blood volume and are released from both the atria and ventricles 
in the presence of increased stretch.  Recent studies of the chronobiology of the RAAS, as well 
as studies of experimental sodium loading in dogs, suggest that the circulating and local RAAS 
might play a more important role than pressure natriuresis in physiological sodium homeostasis 
in this species.106-108 
 
Assessment of RAAS Activity  
Commonly evaluated components of the RAAS include plasma renin activity, direct plasma 
renin levels, plasma or serum aldosterone and AngII concentrations, plasma ACE activity, urine 
and serum Na+/K+ ratios, 24-hour urinary aldosterone excretion, and the UAldo:C.  More 
recently, liquid chromatography – mass spectrometry (LC-MS)/MS has been used to create a 
comprehensive renin-angiotensin system Fingerprint® (Attoquant Diagnostics GmbH Vienna 
Austria) from both blood and tissue samples (Figure 2).109,110   A comprehensive assessment is 
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beneficial, as looking at only 1 or 2 components of this system might be misleading.  For 
example, assessment of only ACE activity during ACEI therapy might suggest very effective 
suppression, yet AngII and aldosterone does ‘break through’ this therapy in some 
patients.15,17,31,106,111,112  Additional information regarding aldosterone metabolism and the 
assessment of RAAS activity in dogs and cats can be found in the supplemental section of this 
review.  
 
Genetic profiling of specific populations and individuals will also likely play a role in the 
development of future RAAS modulation strategies.  RAAS genotype evaluation has led to the 
discovery of polymorphisms such as the insertion or deletion of a base pair in intron 16 of the 
ACE gene in humans and dogs.  These insertion and deletion genotypes impact baseline ACE 
activity and might influence an individual’s response to ACEI therapy.  A more individualized 
and comprehensive approach to future RAAS modulation should include a RAAS profile, RAAS 
genotype, metabolic profile, and diet survey. 
 
Angiotensin II and Aldosterone Excess 
 
Angiotensin II and Aldosterone as cardiovascular and renal toxins 
There is a substantial body of evidence, that AngII and aldosterone likely acting in concert are 
“cardio-“ and “nephrotoxic”(Table 1)48,113,114. This is based on direct (hormone infusion, 
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transgenic animal models) and indirect (RAAS suppression) evidence (Figure 3 and 
supplemental Table 1).  These studies link the fibrosis that attends the pathologic remodeling 
caused by excess AngII and aldosterone to myocardial, vascular, and renal (especially 
glomerular) dysfunction.  The mechanisms by which increased AngII and aldosterone levels lead 
to fibrosis are multifactorial and likely involve stimulation of fibroblasts, generation of ROS, 
inflammation, and upregulation of transcription factors such as nuclear factor kappa B, cytokines 
such as transforming growth factor beta and tumor necrosis factor alpha, and upregulation of 
molecules such as plasminogen activator inhibitor-1.12,115-122 Ultimately, these changes lead to 
increased collagen gene expression and synthesis, as well as decreased fibrinolysis.  Excess 
AngII and aldosterone also directly lead to vascular endothelial dysfunction via the 
vasoconstrictive effects of AngII, increased endothelin expression, inhibition of nitric oxide 
synthase, cyclooxygenase-2 activation, enhanced generation of ROS, and non-genomic effects, 
such as activation of protein kinase C.11,123-127  
 
RAAS activation also contributes to the immune cell infiltration that contributes to the 
inflammation and fibrosis that attends renal ischemia, myocardial infarction, and systemic 
hypertension.128-130 More specifically, the MR on macrophages has been implicated in 
polarization of the macrophage population from the anti-inflammatory M2 subtype to the 
inflammatory M1 subtype, perpetuating inflammation and tissue remodeling.130-133 Antagonism 
or deletion of the macrophage MR is protective against cardiovascular remodeling, even in 
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situations where aldosterone levels are normal.130-132  Oxidative stress also appears to amplify 
inflammation and directly activate the MR or allow glucocorticoids to activate the MR.134,135   
Finally, aldosterone excess decreases baroreceptor sensitivity in healthy humans and dogs with 
experimentally induced heart failure, the result being an undesirable increase in heart rate.8,136,137 
The mechanisms by which neurohormonal activation decreases baroreceptor sensitivity are not 
fully understood.136,138 Decreased baroreceptor-heart rate sensitivity is a key feature of the heart 
failure syndrome139 and is an independent predictor of poor prognosis in people with heart 
failure.140,141  
 
The deleterious effects of excess aldosterone are augmented when the relationship between 
sodium and aldosterone is abnormal.  In the aforementioned animal studies (Table 1, 
supplemental materials), sodium was variably unrestricted or given in excess.  Under normal 
physiologic conditions, sodium supplementation leads to the inhibition of aldosterone release, 
allowing excess sodium to be excreted by the kidney.  In the face of high or even normal total 
body sodium a high aldosterone level is therefore inappropriate.  Further discussion of the 
interplay between aldosterone, sodium status, metabolic state, inflammation, and oxidative stress 
can be found in the supplemental materials.   
 
Suppression of RAAS 
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ACE-inhibitors are widely used in the treatment of cardiovascular and renal diseases in multiple 
species.  The ACEI used most commonly in veterinary medicine have been reviewed and are 
summarized in Supplemental Tables 2 and 3.142 Most ACEI are administered as pro-drugs 
requiring esterification in the liver to become active.  Drugs in this class inhibit ACE and not 
only decrease formation of AngII, but also decrease the degradation of the vasodilatory 
compound bradykinin.   The pharmacokinetic properties of ACEI are complex and their 
disposition during repeated dosing cannot be characterized by a classical noncompartmental 
model.143 The plasma concentration-time profile has initial and protracted elimination phases, 
due to clearance of free drug and release of drug from tissue-binding sites, respectively.144 Using 
circulating plasma ACE activity as a surrogate for efficacy, dosages have been determined for 
several ACEI in animals (Supplemental Tables 2 and 3).  Although circulating ACE activity is 
significantly suppressed at these recommended dosages, clinical trials are required to determine 
efficacy and if there are outcome differences between ACEI.  Variable efficacy amongst ACEIs 
in reducing cardiovascular and renal endpoints might arise from differences in the structure of 
the active moieties, their lipophilicity and bioavailability, affinity for tissue-bound ACE, and 
elimination method.  The clinical relevance of these differences, however, is not known.  As 
ACE is anchored to the cell membrane such that its catalytic site faces the extracellular 
space,145,146 differences in lipophilicity should be less important, except in the case of certain 
centrally-acting ACEI.147 In humans, differences in the clinical efficacy of ACEI has been 
hypothesized to be associated with variation in tissue-ACE affinity57 and this might hold true for 
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dogs and cats, too. Chymase has a greater catalytic efficiency than ACE and is thought to serve 
as the primary generator of AngII in the tissues however, and likely contributes to apparent 
inefficacy of ACEI.74,148-150 Additional explanations for the sporadic failure of ACEI to prevent 
pathologic remodeling as a class, include inadequate aldosterone suppression (aldosterone 
breakthrough), under-dosing, and poor compliance. As previously discussed, novel approaches to 
target tissue RAAS management is likely to be part of future pharmacotherapeutic 
strategies.11,12,40 The most common adverse effects of ACEI in man include cough or 
angioedema, or both, due to the accumulation of bradykinin, as well as increased prostacyclin 
and nitric oxide formation.  These adverse effects are rarely, if at all, recognized in dogs and 
cats.   
 
Angiotensin II receptor blockers prevent AngII from binding its AT1 receptor and were 
developed due to the cough and angioedema adverse effects seen with ACE-inhibition in man.  
Theoretical benefits of ARBs include blockade of the actions of AngII at the AT1R, regardless of 
the pathway of its formation (via ACE or non-ACE pathways, such as chymase).  Also, increased 
circulating AngII, resulting from AT1R blockade, might stimulate the AT2R, thought to be 
counter-regulatory to the maladaptive actions mediated by the AT1R.151 Commonly used ARBs 
are summarized in Supplemental Table 4. As with ACEI, some ARBs are administered as pro-
drugs that require metabolism to an active molecule.  Whether ARBs are superior to ACEI in 
dogs and cats with either cardiovascular or renal disease is not known, though the early 
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experience with telmisartan in cats with hypertension, chronic kidney disease, and proteinuria 
suggests that this may be the case (see below).  A recent meta analysis of studies152-155 of dual 
(ACEI and ARB) therapy in patients with heart failure concluded that until further clinical trials 
are performed, dual therapy should not be routinely administered.156  Controlled clinical trials in 
dogs and cats evaluating combination ACEI and ARB therapy have not been performed.  
 
Spironolactone and eplerenone are synthetic steroidal mineralocorticoid receptor antagonists.  
MR antagonism in the distal renal tubule cells causes an increase in urinary Na+ excretion and a 
decrease in K+ excretion.  In the normal dog, spironolactone decreases K+ excretion, yet does not 
significantly increase urine Na+ excretion and urine volume, even at the high dosage of 
8mg/kg/day.157  In dogs with chronic heart failure and chronic aldosterone excess, however, 
spironolactone likely increases urinary sodium excretion and urine volume.  In the dog, 
spironolactone is quickly absorbed through the gastrointestinal tract into the plasma and is then 
converted to several active metabolites.158,159  The bioavailability in the dog is highest when 
given with food, reaching 80 to 90%.160  During an experimental model of hyperaldosteronism, 
the spironolactone dosage of 2mg/kg PO once daily restors the urinary Na+/K+ ratio to near 
normal, and this is likely the optimal dosage in dogs.160   Because of spironolactone’s ability to 
bind other steroid hormone receptors, adverse effects in people include decreased testosterone 
production, inhibition of testosterone binding its receptor, and increased estradiol levels, which 
can cause gynecomastia in men and menstrual abnormalities in women.161-163 For this reason, the 
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more selective MRA, eplerenone, was developed.  Spironolactone is relatively inexpensive and 
is the most frequently used MRA in veterinary medicine.  Additional pharmacological therapies 
targeting the aldosterone/MR pathway are currently under active investigation.  The third 
generation MRA (finerenone) holds promise, as it also modifies co-regulators of MR 
signaling.164 Fourth generation MRA might provide even greater MR selectivity, targeting the 
MR in specific tissues and possibly modulating only specific transcriptional functions.  
 
Direct renin inhibitors (DRI) such as aliskiren theoretically prevent the initiation of the renin-
angiotensin cascade.  First generation DRIs have not proved to be a panacea for cardiovascular 
and kidney diseases, however, and next generation DRIs have been developed and evaluation of 
their efficacy is underway.165,166   There are currently no studies of DRIs in veterinary patients.  
First generation aldosterone synthase inhibitors unfortunately lack selectivity and decrease 
cortisol production.167  For this reason, more specific, next generation aldosterone synthase 
inhibitors are being developed.168   
 
Novel RAAS modulators include neprilysin inhibitors, recombinant human ACE2, and chymase 
inhibitors.  Inhibition of the neutral endopeptidase, neprilysin, decreases the breakdown of 
endogenous vasoactive peptides, including natriuretic peptides, bradykinin and adrenomedullin.  
When the neprilysin inhibitor, sacubitril, was combined with an ACEI, the frequency of 
angioedema and cough in people was unacceptably high.169 A new combination product 
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(Entresto®), therefore, pairs sacubitril and the ARB valsartan.  This combination was evaluated 
in a large human clinical trial, where it was superior to ACE inhibition alone in reducing the risk 
of death and hospitalization for patients with heart failure with reduced ejection fraction 
(HFrEF).170  This new drug is now a class I recommendation for treatment of HFrEF in 
humans.171  In dogs with RAAS activation secondary to sodium restriction, Entresto® (sacubitril 
dosed at 15mg/kg PO q24h) led to a sustained reduction in circulating aldosterone levels when 
compared to dogs treated with either placebo or valsartan.172  This combination has also been 
evaluated (sacubitril dosed at 20mg/kg PO q12h) in a small study of dogs with ACVIM stage B2 
MMVD173 (Figure 4) and was well tolerated during the 30-day trial.174  Another novel 
therapeutic target is the ACE2 enzyme.  This enzyme is considered counter regulatory to the 
vasoconstrictive and fluid retentive aspects of RAAS, as it catalyzes the conversion of AngII to 
the vasodilatory, anti-inflammatory, anti-fibrogenic peptide Ang(1,7).175-178Human recombinant 
ACE2 has been evaluated in 1 small study in people with acute and chronic heart failure where it 
was found to normalize AngII levels and increases levels of the beneficial Ang(1,7) 
metabolite.110 Finally, based on the likely role of chymase in the local generation of angiotensin 
peptides, such as AngII, chymase inhibitors offer an additional approach to RAAS modulation in 
cardiovascular and renal diseases.  Aside from sacubitril/valsartan, these novel RAAS 
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Studies in humans have shown the benefits of ACEI in the treatment of systolic heart failure, 
associated with moderate to severe179 and mild to moderate symptoms.180,181 Veterinary 
clinicians have had experience with enalapril, captopril, benazepril, lisinopril, imidapril, 
alacepril, and ramipril (Supplemental Tables 2 and 3). Of these, only enalapril and benazepril, 
and to a lesser degree imidapril and ramipril, have been extensively studied.  The benefits of 
ACE-inhibition as part of the therapy of heart failure have been demonstrated in multiple, 
placebo- or drug-controlled clinical trials in dogs with heart failure (Figure 5).182-186 The first, 
randomized placebo controlled clinical trial evaluating enalapril in dogs with CHF due to 
naturally occurring heart disease (either MMVD or dilated cardiomyopathy; DCM) showed an 
improvement in short-term clinical and hemodynamic variables (namely pulmonary capillary 
wedge pressure and pulmonary edema scores).187  A subsequent study, found that enalapril was 
associated with an improvement in several clinical variables (including heart failure 
classification, pulmonary edema score, mobility, attitude, and cough frequency).185  
Improvement in all of these variables was significant in the DCM group, whereas only 
improvement in cough and mobility parameters reached significance in the MMVD group.185  
Two randomized, placebo controlled studies in dogs with CHF due to MMVD or DCM 
subsequently showed an improvement in survival time and delay in the time to worsening of 
heart failure.183,184  This benefit was no longer statistically significant when only the DCM 
subgroup was analyzed, yet low numbers in the DCM groups in these studies make interpretation 
of this result difficult and larger studies of RAAS suppression in DCM are needed.  Additional 
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studies have found that imidapril is non-inferior to enalapril and to benazepril.182,186  In a U.S. 
FDA pivotal trial (double-blind, active-control), the outcome of dogs in CHF due to MMVD and 
DCM, was compared between those treated with enalapril plus standard therapy vs. those 
receiving standard therapy plus the inodilator, pimobendan (Vetmedin®).188 There was no 
difference between treatment groups in the primary endpoint of treatment success or in the heart 
insufficiency and pulmonary edema scores. Total deaths due to CHF at study end (day 56) were 
identical between groups at 14%.  A subsequent European study comparing pimobendan and the 
ACEI, benazepril, showed modest survival benefit in those receiving pimobendan.189 
 
While the use of ACEI in canine CHF is well accepted, the data for ACEI are less robust for 
dogs with cardiac disease, prior to the onset of CHF (ACVIM Stages A and B; Figure 4).  There 
have been 4 studies addressing this, 2 prospective, double blind, placebo-controlled trials 
(enalapril vs. placebo) and 2 retrospective studies (benazepril vs. no therapy).  The MMVD 
studies are summarized in Figure 5.  The first of these looked at dogs with MMVD where 
approximately half were ACVIM Stage B1 and half were Stage B2.  Enalapril was dosed at 0.37 
mg/kg/day.190 Of these 229 dogs (all Cavalier King Charles Spaniels; CKCS), 43% and 42% in 
the treatment and placebo groups, respectively, reached the endpoint, onset of CHF.  The second 
study191, also a placebo-controlled, double-blind study in dogs with MMVD, included 23 breeds, 
with all 124 dogs shown by echocardiography and radiography to be in ACVIM Stage B2 
cardiac disease.  The treatment group received enalapril at an average dosage of 0.45 mg/kg/day.  
 23 
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The result was a significant (P<0.02) improvement in all-cause mortality.191 A retrospective 
study of dogs with ACVIM Stage B1 MMVD, which had received either an ACEI (benazepril) 
or no treatment concluded that dogs receiving benazepril had a significantly longer survival time 
and fewer cardiac events, including cardiac death.192 A retrospective study of 91 Doberman 
Pinchers with occult DCM, which had received either an ACEI (benazepril) or no treatment 
concluded that dogs receiving benazepril had a significantly longer median time to onset of overt 
DCM.193  
 
In the aforementioned study192, the CKCS did not benefit from RAAS suppression, when 
compared to other breeds.  This raises the question of pharmacogenomic differences amongst 
dog breeds.  Recently a single nucleotide polymorphism in intron 16 of the ACE gene in a group 
of 31 dogs (including 10 CKCS) has been described.194  The ACE activity in dogs with the 
polymorphism was significantly lower than those without, yet both groups had significant 
suppression of ACE activity after 2 weeks of ACEI therapy.  Six of the 10 CKCS carried the 
polymorphism, which provides support to the concept, held by some, that the RAAS of the 
CKCS may not truly represent the species as a whole.  Further study is necessary to determine 
whether differences in RAAS phenotypes impact the response to RAAS suppressive therapy and 
the natural history of cardiac disease in this breed.   
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In dogs with experimentally created mitral regurgitation, captopril therapy led to a fall in total 
peripheral resistance index, decrease in regurgitant fraction, and increase in forward ejection 
fraction as compared to untreated controls.195 Conversely, the use of either an ACEI or ARB was 
found to exacerbate the left ventricular dilation and extracellular matrix loss in other studies of 
experimentally created mitral regurgitation in dogs.82,83 These acute to subacute models add 
valuable insight to the pathophysiology of left ventricular volume overload due to mitral 
regurgitation, yet further study is needed in patients with naturally occurring MMVD.  Overall, 
the effect of ACE-inhibition in pre-clinical MMVD might be variable among dogs.  Whereas 
improvement might result from reduced afterload, decreased size of the regurgitant orifice, and 
an antifibrotic effect in later stages, detrimental effects might arise from blockade of the 
inotropic effects of AngII and possible potentiation of extracellular matrix degradation and 
disruption of myocyte stability in the early stages of remodeling.75 
 
The recently completed placebo-controlled, double blind EPIC trial enrolled dogs of various 
breeds with ACVIM stage B2 MMVD with radiographic and echocardiographic evidence of 
cardiomegaly. This study showed that the inodilator pimobendan significantly prolonged the pre-
clinical period in this cohort of dogs.196  Compared to the VETPROOF trial, the EPIC trial had 
more strictly defined cardiomegaly entry criteria and enrolled over 2.5 times as many dogs.  The 
relatively narrow 95% confidence interval of the hazard ratio for the CHF component of the 
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primary endpoint in the EPIC trial supports the benefit of pimobendan in the cohort studied.  A 
similar hazard analysis is not available for the VETPROOF data. 
 
Three large human studies197-199 have shown a clear benefit from the inclusion of broader RAAS 
suppressive therapy in the treatment of HFrEF with the addition of a MRA to standard therapy, 
including an ACEI or ARB.  The ground breaking RALES (ischemic and non-ischemic heart 
disease, NYHA III-IV) and EPHESUS (post-myocardial infarction) studies evaluated human 
patients with severe HFrEF.   The EMPHASIS-HF study (ischemic and non-ischemic heart 
disease) evaluated patients with mild to moderate HFrEF.  In these studies, a MRA 
(spironolactone or eplerenone) was added to optimal heart failure therapy including RAAS 
suppression (either an ACEI or ARB) and beta blockade in the latter 2 studies. Each of these 3 
studies showed a reduction in mortality and cardiac-associated hospitalization.  These 
significantly positive results have led to the recommendation in recent guidelines that MRA be 
used as a standard therapy in the treatment of HFrEF.200  Furthermore, the clinical benefit 
associated with addition of the MRA  in these studies was seen in people with normal, low, and 
elevated blood aldosterone levels at study outset.  The changes in patient neurohormonal profiles 
during chronic spironolactone therapy was monitored in a subset of patients in the RALES 
trial.201 The patients in the spironolactone group had significantly increased circulating AngII 
and aldosterone levels at 3 and 6 months when compared to people receiving placebo.  These 
increases were hypothesized to result from failure of an aldosterone-generated negative feedback 
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loop to reduce renin secretion from the juxtaglomerular apparatus, though local tissue production 
of AngII and aldosterone could also be contributing.  As there was a survival benefit associated 
with spironolactone, the impact of these hormone increases are likely mitigated by antagonism of 
the MR. It is currently not known if these increased concentrations of circulating AngII and 
aldosterone secondary to receptor antagonism have any receptor-independent effects.   
 
On average, plasma aldosterone concentrations in dogs with naturally occurring MMVD and 
DCM (both asymptomatic and with CHF) are higher than that of controls.35,202  In dogs with 
heart failure due to MMVD, 1 study found that, on average, dogs treated with enalapril had an 
initial decline in plasma aldosterone concentrations, when first re-evaluated after 3 weeks of 
treatment.  This was followed by an increase in average plasma aldosterone concentration, above 
baseline levels, 6 months after initiation of treatment.37 Another study, however, showed a 
significant decrease in plasma aldosterone concentrations in all but 1 of 7 dogs with MMVD and 
CHF, after initiation of captopril.35 Additionally, studies in dogs using pharmacologic RAAS 
activation and experimentally-induced heart failure have found rising aldosterone levels despite 
ACEI therapy.38,203-207 Regardless of its frequency, chronic neurohormonal activation has 
consequences and has been linked to pathologic remodelling in dogs with naturally occurring 
heart disease.208 Overall, these data add support for the adjunctive use of a MRA in dogs with 
heart disease.  Although low-dosage spironolactone (0.5mg/kg PO q24h) did not significantly 
impact survival in dogs with advanced CHF due to either MMVD or DCM, a subsequent double-
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blind, placebo-controlled field study in 212 dogs with MMVD and mild to moderate heart failure 
demonstrated a significant reduction in risk of morbidity and mortality due to heart disease with 
the addition of spironolactone (2mg/kg PO q24h) to ‘standard therapy’ (ACEI, furosemide ± 
digoxin).209,210  
 
The role of spironolactone in the treatment of heart failure, due to ventricular diastolic 
dysfunction with preserved ejection fraction (HFpEF) is an area of on-going research.  
Pathological activation of the RAAS and, in particular, hyperaldosteronism, are implicated in the 
pathologic ventricular remodeling and diastolic myocardial dysfunction in hypertrophic 
cardiomyopathy (HCM) in humans.122 Small studies in humans with HFpEF have shown that 
MR blockade, with spironolactone, improves diastolic function.211,212 The addition of 
spironolactone to existing heart failure therapy was recently evaluated in a large, placebo-
controlled, double blind study of people with symptomatic HFpEF (excluding infiltrative or 
hypertrophic cardiomyopathies).  This study did not result in a significant survival benefit or 
reduction in hospitalization for heart failure.  However, there were substantial differences in 
patient response among geographic areas, and post-hoc subgroup analyses raised concerns about 
disparities in actual use of spironolactone and heart failure severity (less severe) in the 
Russian/Georgian patients.213-215  Overall, the incidence of hospitalization for heart failure was 
significantly lower in the spironolactone group as a whole and the use of spironolactone was 
associated with significant improvement in the quality of life score.213,216  In a separate study of 
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patients with HFpEF, spironolactone was associated with improved exercise capacity.217 A 
second clinical trial of spironolactone in the treatment of HFpEF is on-going 
(https://clinicaltrials.gov/ct2/show/NCT02901184?term=SPIRRIT&rank=1).    
 
Plasma aldosterone concentration is elevated above normal in Maine coon cats with 
asymptomatic HCM.218 Short-term (4 months) use of spironolactone (2 mg/kg PO q12h) in these 
asymptomatic cats did not, however, provide reduction in left ventricular mass or improvement 
in an echocardiographic parameters of diastolic function, and 4 of the 13 cats treated with 
spironolactone developed ulcerative facial dermatitis.219 A double-blinded, placebo-controlled 
clinical trial has more recently evaluated the use of spironolactone (1.7 to 3.3 mg/kg PO q24h) in 
client-owned cats with heart failure due to cardiomyopathy, the majority being afflicted with 
HCM.220 All cats (n=20) were also receiving furosemide and an ACEI.  Significantly fewer cats 
receiving spironolactone reached the primary endpoint (cardiovascular death), compared to those 
receiving placebo. Also, no cat receiving spironolactone experienced ulcerative facial dermatitis.  
Because of a small sample size and disparities in disease severity between the 2 groups at 
baseline, the authors concluded that these results are promising, yet additional studies evaluating 
spironolactone in cats with HCM are warranted.   
 
Systemic hypertension  
 29 
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Suppression of RAAS activity with ACEI, ARB and MRA, alone or in combination has been 
shown to improve blood pressure control in people with systemic hypertension.221-223 Whereas in 
people, systemic hypertension (HTN) is usually primary (essential), in dogs and cats it is usually 
secondary to an underlying renal or endocrine disorder.  In dogs, HTN secondary to chronic 
kidney disease (CKD), is often treated with RAAS suppression (ACEI or ARB).224 
Hyperadrenocorticism is a common endocrine disease in the dog and is often complicated by 
HTN, especially in dogs with untreated adrenocortical tumors.225,226 The mechanisms involved in 
HTN in dogs with hyperadrenocorticism are multifactorial and the general approach to therapy is 
an ACEI alone or in combination with amlodipine.  Dogs with adrenocortical tumors have 
significantly higher plasma aldosterone concentrations, when compared to normal dogs and dogs 
with pituitary-dependent hyperadrenocorticism226, and may benefit from the addition of an 
MRA.  The role of hyperaldosteronism in dogs with hypertension, secondary to pituitary 
dependent hyperadrenocorticism, is unclear226-228, as HTN often persists despite medical therapy 
and control of the hyperadrenocorticism.225 In these cases, the addition of an MRA should be 
considered.   
 
In cats, HTN, is usually secondary to renal and/or endocrine disease (e.g. hyperthyroidism and 
various adrenal diseases).  In this species, HTN is a common cause of left ventricular 
hypertrophy, diastolic dysfunction, and other target organ damage.  Plasma aldosterone 
concentrations and the aldosterone to renin ratio in azotemic, hypertensive cats have been shown 
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to be significantly elevated, as compared to normotensive cats.229 In the non-azotemic, 
hypertensive cats in this study, plasma aldosterone concentration was also elevated, but 
independent of plasma renin activity, which was actually depressed in this group.  In this “low-
renin” group, the cats’ aldosterone concentrations and aldosterone to renin ratios were not 
supportive of hyperaldosteronism.  In fact, their neurohormonal profile was similar to that of 
low-renin hypertension, which is diagnosed disproportionately in human patients of African 
ancestry. In humans, low-renin hypertension is most often due to either a low-renin essential 
hypertension or primary aldosteronism.  In people, the MRA, eplerenone, and the ARB, losartan, 
are equivalent in lowering blood pressure in the high-renin patient, yet eplerenone is superior to 
losartan in the low-renin patient.230 Despite this, the authors are unaware of studies using MRA 
therapy in cats with hypertension.  
  
A recent study in normal laboratory cats showed that the ARBs, telmisartan and irbesartan, and 
the ACEI, benazepril, significantly attenuated an AngI-induced blood pressure response, whereas 
losartan did not.231 The effect of telmisartan was significantly greater than that of the other 3 
drugs, 90-minutes after oral administration.  Telmisartan and benazepril were also compared 24-
hours after their oral administration and telmisartan, again, led to a more significant attenuation 
of an AngI-induced blood pressure rise.  A recent clinical field study showed that telmisartan 
was tolerated and lowered mean arterial blood pressure when compared to placebo in cats with 
HTN that was either idiopathic or secondary to chronic kidney disease (CKD) or 
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hyperthyroidism.232  This study excluded cats with pretreatment blood pressures >200mmHg and 
further study is still needed in this cohort.  Finally, circulating RAAS activation in cats is not 
always associated with the development of hypertension, as demonstrated in studies of cats with 
hyperthyroidism and CKD.233,234 Amlodipine, a commonly used antihypertensive agent in both 
dogs and cats, is known to cause aldosterone levels to rise in normal dogs38, yet this does not 
appear to be the case in cats with naturally occurring systemic hypertension.229 In summary, the 
role of RAAS in feline hypertension appears to be complex and, as yet, not adequately defined.  
 
Addition of a MRA is increasingly employed in humans with resistant hypertension, already 
receiving an ACEI and/or ARB.221-223 A recently completed randomized, placebo controlled 
clinical trial found that spironolactone was superior to the addition of either a beta blocker or an 
alpha-1 blocker in patients with resistant systemic hypertension (persistent despite triple therapy 
with an ACE, ARB, and calcium channel blocker).235 From this study, it appears that 
spironolactone is the best additional drug for such resistant systemic hypertension.  MRA add-on 
therapy in dogs and cats with systemic hypertension has not yet been evaluated in veterinary 
patients.   
 
Proteinuric kidney disease 
Proteinuria, a marker of kidney injury, is likely a predictor of increased risk for disease 
progression, and might play a causal role in progression of glomerular disease.236-238 Clinical 
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trials involving RAAS suppression in people with proteinuric kidney disease are summarized in 
Supplemental Table 5.  In people, the combination of ACEI and ARB is usually more effective at 
reducing proteinuria in various forms of kidney disease than either therapy alone.  The reduction 
in proteinuria does not, however, always translate to improved renal outcomes (need for dialysis, 
increasing creatinine, and fall in estimated GFR) and is sometimes associated with increased 
incidence of hyperkalemia and acute injury when compared to monotherapy.239,240 The addition 
of a MRA to an ACE or ARB (alone or together) has also been shown to augment proteinuria 
reduction in people with either systemic hypertension, diabetic nephropathy, or chronic kidney 
disease with and without systemic hypertension.241,242  The addition of an MRA to an ACEI or 
ARB, however, increases the risk of hyperkalemia in patients with chronic kidney disease.113   
The effect of finerenone on cardiovascular and renal outcomes in human patients with diabetic 




ease&rank=1).  Combination RAAS suppression and the addition of a MRA to standard 
pharmacotherapy, has not been studied dogs and cats with naturally occurring renal disease.   
 
The benefit of RAAS suppressive therapy in canine proteinuric CKD, including idiopathic 
glomerulonephritis, has been demonstrated in experimental models and small clinical studies.243-
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246 In uninephrectomized dogs, with experimentally induced diabetes mellitus and resultant 
proteinuria, treatment with lisinopril lowered glomerular capillary pressure, attenuated the 
development of glomerular hypertrophy, and reduced proteinuria significantly, when compared 
to untreated dogs.244 In a 5/6-nephrectomy model of CKD, dogs treated with enalapril had, on 
average, a systolic BP that was 5-15 mmHg lower than their untreated counterparts.  This 
difference was significant at 3 months, yet not at 6 months.  Furthermore, treated dogs had lower 
urine protein to creatinine ratios (UP:C) and significantly lower renal tubular and glomerular 
lesion scores.243 Benazepril significantly reduces azotemia and systemic blood pressure in a 
short-term study of experimental renal insufficiency in dogs induced by a 7/8 nephrectomy 
model of CKD.247 In a double-blind, randomized clinical trial of dogs with biopsy-proven, 
membranous and membranoproliferative glomerulonephritis, treatment with enalapril 
significantly lowered blood pressure, UP:C and UP:C corrected for GFR, while these indices 
rose in the placebo group.245  In another study of benazepril vs. placebo in dogs with CKD, 
benazepril therapy was associated with a significant increase in GFR over the 180-day study, 
something not seen in the placebo group.246 In this study the authors hypothesize that the 
increased GFR could have been due to reduced glomerular capillary hypertension, decreased 
release of extracellular matrix and collagen from mesangial and tubular cells, and potentially 
decreased glomerular and interstitial fibrosis, though these factors were not directly evaluated.   
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The magnitude of proteinuria in dogs newly diagnosed with CKD appears to be related to 
prognosis248, as a reduction in proteinuria may prolong survival. Dogs with a UPC > 1.0 are 
known to have a relative risk of uremic crisis or death 3 times greater than dogs with a UPC < 
1.0. In a small study of X-linked, hereditary nephritis, dogs treated with high-dose enalapril 
(2mg/kg PO q12h) had a significantly slower progression of proteinuria and survived 
significantly longer than those untreated.249 For these reasons, it is now well accepted, that 
ACEI, administered chronically to both human and veterinary patients with naturally occurring 
proteinuric renal disease, are beneficial.245,247,250-255 Mechanisms for this improvement are 
postulated to be the antihypertensive effect, reduction of AngII-induced mesangial cell 
proliferation, and renal vasodilatory effects of ACEI, the latter resulting in a treatment-induced 
fall in renal filtration pressure and proteinuria.250,252,253 Therefore, RAAS suppression with an 
ACEI or, less commonly, an ARB, is considered standard of care for dogs with glomerular 
disease and reduction in proteinuria is considered a surrogate therapeutic endpoint.256 Neither 
dual RAAS blockade with ACEI and ARBs, nor the addition of a MRA to standard 
pharmacotherapy, have been studied in dogs with naturally occurring renal disease.  Controlled 
studies are needed to evaluate the effect of these combinations. There is no consensus regarding 
RAAS suppressive therapy in dogs with non-proteinuric CKD.   
 
The RAAS is activated in experimental and natural CKD in cats. 234,257 Benazepril has been 
evaluated in cats with CKD (proteinuric and non-proteinuric), and it is well tolerated and 
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significantly reduces proteinuria.258  Although this study did not document a benefit of 
benazepril therapy on renal survival (endpoint of death or euthanasia due to renal disease or need 
for parenteral fluid therapy), renal survival times were inversely related to initial UP:C.  
Importantly, proteinuria has been shown to predict progression of azotemia259 and is negatively 
associated with survival in cats with chronic renal disease260 and systemic hypertension.261 More 
recently the ARB, telmisartan, has been compared to benazepril in cats with chronic kidney 
disease and proteinuria.262 Telmisartan was non-inferior to benazepril in preventing an increase 
in proteinuria over the 6-month treatment period and led to a significant reduction in proteinuria 
at all time points, whereas the reduction seen in the benazepril group did not reach significance.  
As with dogs, combination RAAS blockade has not been evaluated in cats.  Finally, benazepril 
has been shown to lower blood urea nitrogen, serum creatinine concentration, and blood pressure 
in cats with polycystic kidney disease.255 This is in stark contradistinction to the findings in 
human polycystic kidney disease, in which patients so afflicted did not benefit from ACEI.253   
 
Safety of RAAS Suppressive Therapy  
We have learned through clinical experience with ACEIs that their negative impact on kidney 
function is minimal, even in the face of severe heart failure. When azotemia is observed, ACEIs 
are usually being administered in conjunction with diuretics, sodium restriction, and sometimes 
vasodilators, often with resultant hypotension. Typically, diuretic cessation or reduction in 
dosage results in the improvement or resolution of azotemia.263 In studies of enalapril in NYHA 
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phase III and IV heart disease (moderate to severe heart failure), due to MMVD and DCM, there 
was actually a lower incidence of azotemia in the enalapril-treated than the placebo-treated 
groups.183,185,187 Additionally, in a placebo-controlled, double-blind evaluation of enalapril 
(average dosage of 0.45 mg/kg/day) in aged, small breed dogs with ACVIM Stage B2 (Figure 4) 
MMVD, there was no difference between groups in average serum creatinine concentration at 
any time point, number of dogs developing renal failure, or change in serum creatinine 
(evaluated every 3 months during the study duration; Supplemental Figure 2).264 
 
A safety analysis of dogs involved in the study of Bernay and colleagues showed that those 
receiving spironolactone, in addition to standard therapy (including an ACEI), were not at higher 
risk for adverse events (such as death from renal disease and abnormalities in serum sodium, 
potassium, urea nitrogen, and creatinine), when compared with dogs receiving placebo and 
standard therapy.265 In fact, mortality due to cardiac disease, kidney disease, or both was lower in 
the group treated with spironolactone.  Importantly, dogs receiving spironolactone in addition to 
conventional therapy for heart failure (loop diuretic, ACEI, and pimobendan) did not have a 
greater incidence of hyperkalemia.  In a study of Doberman pinschers with occult DCM, 
significant increases in serum potassium concentration (vs. individual baseline values) were seen 
in dogs receiving both spironolactone and an ACEI.266 Although the authors deemed these 
changes to be clinically insignificant, the serum potassium concentration exceeded the reference 
interval in 50% of dogs and regular monitoring of serum electrolytes and renal values (as often 
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as every 3 months) was recommended for Doberman pinschers receiving spironolactone and 
ACEI.  Overall, regular monitoring of serum electrolytes and renal values is prudent in all 
animals receiving vasodilators and diuretics, including spironolactone and ACEI.  Finally, 
spironolactone in combination with an ACEI appears to be safe, when used to treat dogs with 




Sustained RAAS activation adversely affects the heart, vessels, and kidneys.  The more we learn 
about this system, the broader and more complex its web becomes, and redundancies that bypass 
our therapeutic blockade or inadvertent suppression of beneficial components of this system may 
be part of what reduces the efficacy of our current RAAS suppressive therapies.  The future of 
medical therapy for cardiovascular and kidney diseases will therefore likely not include more 
comprehensive blockade, yet rather will include a more adept modulation of this system.  This 
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Figure legends 
Figure 1.  
The RAAS scheme: factors that lead to the release of renin from the juxtaglomerular cells of the 
kidney and the ‘target organs’ of AngII, whose actions (both physiologic and pathologic) are 
primarily mediated by the AT1R.  The actions of AngII at the AT2R are thought to counter those 
of the AT1R. The AT2R is likely of greater importance in the developing fetus, yet might be up-
regulated in certain disease states in adults.  Angiotensin II is also a major secretagogue for 
aldosterone, which acts via the MR to increase sodium retention in the kidney and also amplifies 
the pathologic effects of AngII in the heart, kidney, and vasculature.  AngI, angiotensin I; AngII, 
angiotensin II, AT1R, angiotensin type 1 receptor; AT2R, angiotensin type 2 receptor; CO, 
cardiac output; MR, mineralocorticoid receptor; SNS, sympathetic nervous system.  
 
Figure 2. 
The renin-angiotensin-aldosterone system peptide cascade (RAAS Fingerprint®) is illustrated as 
a pedigree starting at Angiotensin 1. Each intersection represents a specific peptide fragment 
symbolized by colored spheres; Enzymes involved in the reactions are annotated on connecting 
lines. Size of spheres and numbers beside them represent absolute concentrations of angiotensins 
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(pg/ml, median values) in serum samples from 6 middle-aged, healthy, male beagles; the 
concentrations were analyzed by mass spectrometry. Angiotensin (1,7) and (1,5) are breakdown 
products of both angiotensin I and II.  The novel peptides angiotensin (1,12) and angiotensin 
(1,25) may be directly derived from angiotensinogen and serve as precursors for angiotensin 
peptides such as AngII.  AngI, angiotensin I; AngII Angiotensin II; AngIII, Angiotensin III; Ang 
IV, Angiotensin IV; Aldo, aldosterone; AP, aminopeptidase; AT1R, Angiotensin Type-1 
Receptor; NEP, neutral endopeptidase.  
 
Figure 3.  
Schematic representation of experiments carried out by Brilla and Weber7,268-271 using rats with 
varying kidney function and experimental hypertension.  Panel A. Normotensive control rat 
heart, aorta, renal arteries, kidneys, and normal angiotensin II and aldosterone production.  B) 
unilateral renal ischemia (unilateral renal artery banding) model with infra-renal aortic banding 
C) aldosterone infusion with high-sodium diet, and D) infra-renal banding.  Increased circulating 
angiotensin II and/or aldosterone occur in models B and C, which are characterized by interstitial 
and perivascular fibrosis of both the hypertrophied left and non-hypertrophied right ventricles.  
In model B the angiotensin converting enzyme inhibitor, captopril, prevented interstitial and 
perivascular fibrosis in rats with renal ischemia, yet did not prevent this remodeling in rats with 
aldosterone infusion and high sodium diets (model C).  When models B and C were treated with 
spironolactone before and after the induction of hypertension.  The rats developed left ventricular 
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hypertrophy as expected, yet had significantly less interstitial and perivascular myocardial 
fibrosis, when compared to untreated controls. ACEI, angiotensin converting enzyme inhibitor; 
Aldo, aldosterone; AngII, angiotensin II; LV, left ventricle, LVH, left ventricular hypertrophy, 
MRA mineralocorticoid receptor antagonist; RV, right ventricle.  
 
Figure 4. 
The American College of Veterinary Internal Medicine (ACVIM) Classification of Cardiac 
Disease.  From at risk of heart failure to refractory heart failure.173 
 
Figure 5.  
Seven RAAS suppression clinical trials, 6 of which are of placebo-controlled, double blind, 
multicenter design, are redrawn from the original publications.37,182-186,190-192,210  All studies were 
funded by pharmaceutical companies.  
 
The first 4 Kaplan-Meier curves represent trials involving dogs in congestive heart failure 
(ACVIM, Stage C2; CHF), due to mitral valve disease (MMVD) or dilated cardiomyopathy 
(DCM).  Only the 4th panel was comprised exclusively of dogs with MMVD.  All studies in 
panels 5 through 7 were made up entirely of dogs with asymptomatic MMVD (ACVIM Stage B).  
Panels 1 and 2 depict prospective, double blind clinical trials, involving enalapril. While the third 
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graph contains data from a retrospective study of dogs treated with benazepril vs. those left 
untreated in ACVIM Stage B1.  
 
Symptomatic (panels 1 through 4)  
Panel 1. The LIVE trial was 1 of the first placebo-controlled, double-blind clinical trials in 
veterinary cardiology. Significant improvement in survival (death or removal from study) was 
documented in a population of dogs in CHF (ACVIM, Stage C2), due to MMVD or DCM, when 
treated with enalapril plus standard therapy, as compared to placebo plus standard therapy. 
Placebo plus standard therapy, dashed line. Enalapril plus standard therapy, solid line. 
 
Panel 2. The BENCH Trial compared benazepril to placebo in dogs with CHF due to MMVD or 
DCM, and demonstrated significant benefit in survival (time to death or removal from the study 
for worsening clinical signs), and quality of life, in the dogs receiving benazepril. Placebo plus 
standard therapy, dashed line. Benazepril plus standard therapy, solid line.  
 
Panel 3. The FIRST (placebo-controlled, double-blind) and EFFIC trials (open label) 
respectively compared imidapril (solid line) or ramipril (not shown) to an established ACEI, 
enalapril (dashed line), in treating dogs with MMVD or DCM, NYHA Stage 2-4. Data are shown 
only for the 12-month, placebo-controlled FIRST trial.  Both studies demonstrated comparable 
survival and quality of life scores between imidapril and the control ACEI. 
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Panel 4. The CEVA Spironolactone Trial compared spironolactone plus standard therapy 
(including benazepril) to placebo, in a prospective, double-blind trial involving dogs in ISACH 
International Small Animal Health Council (ISACHC) classification, II and III, due to MMVD.  
In general, these dogs were in relatively mild heart failure.  Similar to the RALES trial, 
significant survival benefit was realized by the dogs receiving spironolactone along with 
standard therapy.  Placebo plus standard therapy, dashed line. Standard therapy plus 
spironolactone, solid line. 
 
Asymptomatic (panels 5 through 7) 
Panel 5. The SVEP trial involved an approximate 50:50 distribution of dogs with ACVIM Stage 
B1 and Stage B2, (asymptomatic), with treated dogs receiving enalapril, at a dosage of 0.37 
mg/kg/day.190 Of these 229 dogs (all Cavalier King Charles Spaniels), approximately 45% 
reached the defined endpoint, onset of CHF. The 2% benefit seen in the number of days dogs 
remained in the study, free of CHF, between placebo- and enalapril- treated dogs was not 
significant (log-rank test, P = 0.85). Placebo, dashed line. Enalapril, solid line 
 
Panel 6. The VETPROOF compared enalapril to placebo, in a double-blind, placebo-controlled 
trial of dogs in ACVIM B2.  The graph depicting the combined endpoint of survival (all-cause 
death and CHF-free survival), expressed as a Kaplan-Meier curve, for 124 dogs that met entry 
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requirements is presented. Median times to this combined endpoint in the treatment and placebo 
groups were 851 and 534 days (59% difference of 317 days [10.6 months] in heart failure and 
survival benefit), respectively (P = 0.05).  The primary endpoint (time to onset of CHF) was 
prolonged by enalapril vs. placebo, but was not significant (P = 0.06). However, the numbers of 
dogs not in CHF were significantly different between groups on days 500 and 1000, as were the 
curves delineating all-cause mortality.  Placebo, dashed line. Enalapril, solid line 
 
Panel 7. Kaplan-Meier survival curves of dogs treated with benazepril (solid line) or untreated 
(Placebo, dashed line), after the initial diagnosis of ISACHC class Ia (ACVIM Stage B1) 
MMVD, with moderate-to-severe mitral regurgitation, demonstrated with echocardiography.  
While retrospective, this study demonstrates a delay in the onset of CHF in the treatment group.  
This raises the possibility that ACEI may be of benefit even before cardiac remodeling is evident 
and supports the use of ACEI in MMVD, prior to the onset of congestive heart failure.  
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Figure 5. (Option 2) 
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Table 1: Aldosterone and Angiotensin II: Harmful Cardiovascular & Renal Effects 
Adverse Effect Direct effects of 
Angiotensin II 
Direct effects of 
Aldosterone 
Myocardial remodeling:  
Fibrosis, hypertrophy, necrosis, 
apoptosis 
Yes Yes 
Vascular remodeling:  
Hypertrophy, fibrosis 
Yes Yes  
Increase ROS Yes Yes  
Pro-inflammatory (Cytokines, ROS) Yes Yes  
Arrhythmogenic Yes Yes 
Vascular endothelial dysfunction (ET-1, 
vasopressin, acetylcholine-mediated 
vasodilatory dysfunctin)  
Yes Yes  
Systemic hypertension Yes Yes 
Glomerular damage  
Glomerular dysfunction: proteinuria 








+ (fluid retention & SNS) 
Yes 
Baroreceptor dysfunctionHR increase  
Increased SNS tone 
Inotropy 





















ROS, reactive oxygen species, ET-1, endothelin 1; SNS, sympathetic nervous system; HR, heart 
rate. 
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